of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host.

- 2. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 1 wherein said antigen presenting cells are selected from the group consisting of class I major histocompatibility expressing cells, class II major histocompatibility expressing cells, dendritic cells and CD4⁺ cells.
- 3. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 1 wherein said at least one antigen moiety is located at at least one end of at least one of the heavy and light chains of said monoclonal antibody moiety.
- 4. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 3 wherein said at least one antigen moiety is located at the C-terminal end of said at least one of the heavy and light chains of said monoclonal antibody moiety.
- 5. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 4 wherein said at least one antigen moiety is located at the C-terminal end of both said heavy and light chains of said monoclonal antibody moiety.
- 6. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 5 wherein said at least one antigen moiety is directly linked to the C-terminal end of both said heavy and light chains of said monoclonal antibody moiety.
- 7. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 6 wherein said at least one antigen moiety is an inherently weakly-immunogenic antigen moiety.
- 8. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 6 wherein said <u>monoclonal antibody moiety is genetically modified to contain</u> [at least one antigen moiety comprises] a plurality of antigen moieties.
- 9. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 8 wherein said plurality of antigen moieties is a plurality of a single antigen moiety.
- 10. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 8 wherein said plurality of antigen moieties is a plurality of different antigenic moieties.
- 11. (Amended) The <u>recombinant conjugate antibody</u> molecule of claim 7 wherein said at least one antigen moiety is a peptide having from 6 to 100 amino acids and containing at least one epitope.
- 27. (Twice Amended) An immunogenic composition, comprising, as an active component thereof, a conjugate antibody molecule consisting of [comprising] a bivalent monoclonal antibody moiety having the entire heavy and light chains and

specific for a surface structure of antigen presenting cells, said monoclonal antibody moiety genetically modified to contain at least one antigen moiety, each said antigen moiety being located exclusively at a [at least one] preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host, and a pharmaceutically acceptable carrier therefor.

In the Abstract:

Remove the start of a new paragraph in line 15. A new Abstract of the Disclosure is enclosed, incorporating this change.

REMARKS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension three months of the period for response to the Office Action. The prescribed fee is enclosed.

The courtesy of the Examiner in granting an Interview on this application to the applicants' representative, Mr. Michael Stewart, and to Mr. Reza Yacoob, a member of the Patents Department of the assignee company, Connaught Laboratories Limited, is much appreciated. It is believed that the Interview was material in advancing the prosecution of the application, as reflected in the Interview Summary Record. The comments and submissions made herein compliment and supplement those made to the Examiner at the Interview.

The Examiner noted that this application is a continuation of a prior filed application and such status should be reflected on page 1 of the specification. Page 1 of the specification has been amended immediately following the Title to reflect the continuation status of this filing. The abandonment status of the present filing has been included in the continuation reference on page 1.

The Examiner noted applicants' election of the claims of Group I and cancellation of the claims of Group II. Applicants' confirm their election of the claims of Group I, namely claims 1 to 11, 27 and 28. The remaining claims were cancelled.

The Examiner indicated that applicants intended to submit an IDS and PTO-1449. The Examiner indicated that there was no such material in the file.